Kodiak Sciences Announces Completion Of 300-Patient Enrollment In First Pivotal Cohort Of Phase 3 PEAK Trial For KSI-101; Says Topline Data On Track For December 2026
Share
Why It Matters
Kodiak Sciences finished signing up 300 patients for an important eye-disease medicine test, and they're on schedule to share results in December 2026. When a company hits its enrollment goals on time, it shows the medicine might be working and the company is running smoothly.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.